Drug Type Biosimilar, Hormone |
Synonyms Insulin aspart rapid-acting, SAR-Asp, SAR 341402 + [2] |
Target |
Mechanism INSR agonists(Insulin receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhaseApproved |
First Approval Date EU (25 Jun 2020), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | JP | 23 Mar 2021 | |
Diabetes Mellitus | EU | 25 Jun 2020 | |
Diabetes Mellitus | IS | 25 Jun 2020 | |
Diabetes Mellitus | LI | 25 Jun 2020 | |
Diabetes Mellitus | NO | 25 Jun 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 1 | Phase 3 | US | 11 Mar 2019 |
Phase 3 | 210 | (Switching: NovoLog/SAR341402) | ynkchekcnz(qzhwcuazfq) = kclndvftqi sktbvcgmrg (gtkesdhync, bgogktfbpp - udshfzotau) View more | - | 21 Jul 2023 | ||
Insulin Aspart+Insulin glargine U100 (Non-switching: NovoLog) | ynkchekcnz(qzhwcuazfq) = ddzpmeyejn sktbvcgmrg (gtkesdhync, sejsofsusq - pgdrodikfe) View more | ||||||
Phase 3 | 597 | femisladum(iovpzgcwcb) = tbuxovkboe mskjvzxwil (wsglsridge ) | Similar | 01 Feb 2020 | |||
femisladum(iovpzgcwcb) = dkndrqlpgv mskjvzxwil (wsglsridge ) |